Clinical Trials Logo

Mantle Cell Lymphoma (MCL) clinical trials

View clinical trials related to Mantle Cell Lymphoma (MCL).

Filter by:

NCT ID: NCT02914938 Terminated - Clinical trials for Chronic Lymphocytic Leukemia (CLL)

A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin's Lymphoma

Start date: October 2016
Phase: Phase 1
Study type: Interventional

A Three-Arm Study of ME-401 in Subjects with Relapsed/Refractory CLL/SLL or FL, of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

NCT ID: NCT02717624 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Start date: April 20, 2016
Phase: Phase 1
Study type: Interventional

A Phase 1b, Multicenter, Open-label Study of Acalabrutinib in Combination with Bendamustine and Rituximab (BR) or Venetoclax and Rituximab (VR) in Subjects with Mantle Cell Lymphoma

NCT ID: NCT02362035 Active, not recruiting - Multiple Myeloma Clinical Trials

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies

KEYNOTE145
Start date: February 20, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

This study is evaluating the safety, pharmacodynamics (PD), and efficacy of acalabrutinib and pembrolizumab in hematologic malignancies.

NCT ID: NCT02213926 Active, not recruiting - Clinical trials for Mantle Cell Lymphoma (MCL)

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Start date: March 2, 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to characterize the safety and efficacy profile of ACP-196 (acalabrutinib) in subjects with relapsed or refractory Mantle Cell Lymphoma (MCL).